Opioid Dependency Clinical Trial
Official title:
Evaluation of Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy
This is a multi-center, open-label, preference study of two sublingual formulations of buprenorphine HCl, in opioid-dependent patients on buprenorphine maintenance therapy. The objectives of this study are to evaluate the overall preference between two buprenorphine sublingual formulations, after a switch from the marketed tablet (Subutex®) to the new fast dissolving tablet (FDT), in opioid-dependent patients with buprenorphine 8 mg or 16 mg daily maintenance therapy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00772785 -
Study of Probuphine in Patients With Opioid Dependence
|
Phase 3 | |
Completed |
NCT00591617 -
Optimizing Outcomes Using Suboxone for Opiate Dependence
|
N/A | |
Completed |
NCT00913484 -
Disulfiram for Cocaine Abuse in Buprenorphine Treatment
|
Phase 2 | |
Completed |
NCT01262261 -
Re-Treatment Study of Probuphine in Opioid Addiction
|
Phase 3 | |
Terminated |
NCT00269607 -
Naltrexone Implants as Relapse Prevention
|
Phase 2/Phase 3 | |
Completed |
NCT00577005 -
Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients
|
Phase 2 | |
Completed |
NCT01806389 -
A Study of Breastfeeding in Buprenorphine Maintained Women
|
N/A | |
Completed |
NCT00955162 -
Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")
|
Phase 4 | |
Completed |
NCT00727675 -
Chronic Pain and Opioid Dependence Assessment and Treatment
|
N/A | |
Completed |
NCT00742170 -
Transdermal Electroacupuncture for Opioid Detoxification
|
Phase 1/Phase 2 | |
Completed |
NCT01114308 -
A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
|
Phase 3 | |
Completed |
NCT00877591 -
Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications
|
Phase 1 |